BridgeBio Oncology Therapeutics Earnings Call Transcripts
Fiscal Year 2026
-
Three clinical programs targeting RAS and PI3K pathways are advancing, with all major readouts expected in the second half of 2026. Early data show strong efficacy and safety, especially for the KRAS G12C and pan-KRAS inhibitors, and multiple combination studies are underway.
-
Three in-house developed assets target RAS-driven tumors with novel on/off inhibition and selective pathway modulation. Early clinical data show strong efficacy and safety, especially in combination settings, with key data readouts expected in the second half of the year.
-
Three oncology programs showed strong efficacy and safety: 8520 led to high response rates and durable benefit in NSCLC, 818 demonstrated pan-KRAS activity with low toxicity, and 203 achieved target engagement without hyperglycemia. Internal combinations are prioritized, with more data expected in 2026.
-
Promising early clinical data for three RAS pathway inhibitors show high response rates, durable efficacy, and favorable safety profiles in difficult-to-treat cancers. Combination strategies with standard therapies are advancing, with key data updates expected in 2026.
Fiscal Year 2025
-
Three clinical programs targeting RAS and PI3K alpha advanced in 2025, supported by a $380M de-SPAC merger. Key data readouts for all programs are set for 2026, with strategic partnering and portfolio prioritization planned based on results.
-
Three clinical-stage oncology programs targeting RAS and PI3K-alpha are advancing, with BBO-8520 showing strong early efficacy and safety, and additional data from all programs expected in 2025–2026. Financial resources are sufficient to support development through key milestones.
-
The company has rapidly advanced three RAS- and PI3Kα-focused assets into phase I, secured over $800 million in funding, and expects pivotal clinical data readouts in 2025. Early results show strong efficacy and safety, with innovative mechanisms targeting key oncogenic pathways.
-
Recently spun out and now public, the company has secured over $400 million to advance three innovative oncology programs targeting KRAS and PI3Kα. Early clinical data show strong efficacy and safety, with major data readouts expected throughout 2026 to guide future development.
-
Three novel oncology programs are advancing through phase I, targeting KRAS and PI3K alpha mutations with differentiated mechanisms and strong early safety and efficacy signals. Key data readouts are expected in 2025 and 2026, supported by a $480 million cash runway into 2028.